MAZE vs ROL · rev $20.0M vs P/E 41, rev $1.99B
Maze Therapeutics, Inc. Common Stock (MAZE) versus Rollins Inc (ROL) — a side-by-side from cached financials, not a winner call.
Maze Therapeutics, Inc. Common Stock (MAZE) is a biotechnology company listed on US.
Rollins Inc (ROL) is a personal services company listed on NYSE.
Latest reported MAZE revenue for 2026-06-30 was $20.0M. Net income was -$68.9M. Revenue was up 0.0% from 2026-03-31 to 2026-06-30. MAZE currently screens at market cap $525.3M.
Latest reported ROL revenue for 2026-06-30 was $1.99B. Net income was $251.7M. ROL currently screens at market cap $21.73B and trailing P/E 41.4.
MAZE currently screens at market cap $525.3M. ROL currently screens at market cap $21.73B and trailing P/E 41.4.
Not investment advice. Open the MAZE and ROL stock pages for the full models.
Not investment advice.